Health Tidings Mergers & AcquisitionsServier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Servier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Read Post »
Clinical TrialsIdorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Idorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Read Post »
Clinical TrialsPersonalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Personalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Read Post »
Clinical TrialsIdorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Idorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Read Post »
Mergers & AcquisitionsAgios Lands Global Cevidoplenib Rights in Rare Hematology Push Agios Lands Global Cevidoplenib Rights in Rare Hematology Push Read Post »
Clinical TrialsNovartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Novartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Read Post »
New Drug ApprovalShionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Shionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Read Post »
Clinical TrialsBioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC BioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC Read Post »
Clinical TrialsReplimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Replimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Read Post »
Health TidingsUCB, Biogen Report Positive PHOENYCS GO Results in SLE UCB, Biogen Report Positive PHOENYCS GO Results in SLE Read Post »
Health TidingsPfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Pfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Read Post »
Health TidingsRevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC RevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC Read Post »
Clinical TrialsASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... ASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... Read Post »
Clinical TrialsLilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Lilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Read Post »
Clinical TrialsAkeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Akeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Read Post »
Clinical TrialsApalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Apalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Read Post »
Health TidingsIndustry Perspective: What Wockhardt’s ZAYNICH FDA Approval Means for Pat... Industry Perspective: What Wockhardt’s ZAYNICH FDA Approval Means for Pat... Read Post »
Health TidingsOtsuka Reports Positive Phase 3 Results of Centanafadine in Adult ADHD Ahea... Otsuka Reports Positive Phase 3 Results of Centanafadine in Adult ADHD Ahea... Read Post »
Clinical TrialsCogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Cogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Read Post »
Clinical TrialsIncyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Incyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Read Post »
Clinical TrialsPfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Pfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Read Post »
Clinical TrialsImmunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Immunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Read Post »
Clinical TrialsFirst-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... First-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... Read Post »
Health TidingsEU Expands Comirnaty Authorization for Children Under 5 EU Expands Comirnaty Authorization for Children Under 5 Read Post »
Health TidingsMHRA Approves Sanofi’s Rilzabrutinib for Adults with Chronic ITP MHRA Approves Sanofi’s Rilzabrutinib for Adults with Chronic ITP Read Post »
Health TidingsWHO Endorses Regeneron’s Maftivimab for Bundibugyo Ebola Trials WHO Endorses Regeneron’s Maftivimab for Bundibugyo Ebola Trials Read Post »
Health TidingsBMS’s Mezigdomide Hits Phase 3 Goal in Relapsed Myeloma BMS’s Mezigdomide Hits Phase 3 Goal in Relapsed Myeloma Read Post »
New Drug ApprovalFDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes FDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes Read Post »
Clinical TrialsDizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Dizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Read Post »
New Drug ApprovalFDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization FDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization Read Post »
Clinical TrialsPfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Pfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Read Post »
Clinical TrialsAstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... AstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... Read Post »
Health TidingsMerck Advances Calderasib With FDA Breakthrough Therapy Designation in Lung... Merck Advances Calderasib With FDA Breakthrough Therapy Designation in Lung... Read Post »
New Drug ApprovalEuropean Commission Authorizes New VENCLYXTO Regimens for CLL European Commission Authorizes New VENCLYXTO Regimens for CLL Read Post »
Health TidingsPhase 2b Failure Ends Agios’ Tebapivat Program in Lower-Risk MDS Phase 2b Failure Ends Agios’ Tebapivat Program in Lower-Risk MDS Read Post »
Clinical TrialsMajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... MajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... Read Post »
Health TidingsReplimune Aligns with FDA on RP1 Resubmission Path in Advanced Melanoma Replimune Aligns with FDA on RP1 Resubmission Path in Advanced Melanoma Read Post »
Health TidingsFDA Extends Review of Beren’s Adrabetadex NDA for Infantile-Onset NPC FDA Extends Review of Beren’s Adrabetadex NDA for Infantile-Onset NPC Read Post »
Clinical TrialsFDA Updates TREMFYA Label With Structural Joint Damage Data in PsA FDA Updates TREMFYA Label With Structural Joint Damage Data in PsA Read Post »
New Drug ApprovalImfinzi Cuts Recurrence Risk by 32% and Wins FDA Approval in High-Risk NMIB... Imfinzi Cuts Recurrence Risk by 32% and Wins FDA Approval in High-Risk NMIB... Read Post »
Clinical TrialsFDA Prioritizes Review of Zydus’ Saroglitazar for Rare Liver Disease FDA Prioritizes Review of Zydus’ Saroglitazar for Rare Liver Disease Read Post »
Health Tidings Mergers & AcquisitionsPfizer and Innovent Strike Oncology Deal Worth Up to $10.5 Billion Pfizer and Innovent Strike Oncology Deal Worth Up to $10.5 Billion Read Post »
Clinical TrialsZanidatamab–Tislelizumab Triplet Delivers Practice‑Changing Survival Ga... Zanidatamab–Tislelizumab Triplet Delivers Practice‑Changing Survival Ga... Read Post »
Clinical TrialsNervGen Reports Neural Recovery Signals With NVG-291 in Chronic SCI Trial NervGen Reports Neural Recovery Signals With NVG-291 in Chronic SCI Trial Read Post »
Health TidingsLilly Secures Nationwide PBM Coverage for Obesity Portfolio Lilly Secures Nationwide PBM Coverage for Obesity Portfolio Read Post »
Health TidingsFDA Starts Priority Review of Venglustat for Neurological Gaucher Disease FDA Starts Priority Review of Venglustat for Neurological Gaucher Disease Read Post »
Clinical TrialsImmutep Links Eftilagimod Alfa Immune Activation to Survival Benefit Across... Immutep Links Eftilagimod Alfa Immune Activation to Survival Benefit Across... Read Post »
Clinical TrialsOno Reports Encouraging Phase 2 Results for ONO-2808 in MSA Ono Reports Encouraging Phase 2 Results for ONO-2808 in MSA Read Post »
Clinical TrialsIpsen Presents New Data Reinforcing IQIRVO® in PBC at EASL 2026 Ipsen Presents New Data Reinforcing IQIRVO® in PBC at EASL 2026 Read Post »
Health TidingsFDA Grants Priority Review to Cogent’s Bezuclastinib in Second-Line GIST FDA Grants Priority Review to Cogent’s Bezuclastinib in Second-Line GIST Read Post »
